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Abstract
Objective: To establish the prevalence of hyperhomocysteinemia in women with placental abruption or infarction. Design: Forty- 
six women with normal pregnancy outcome (controls) and 84 women with placental abruption or infarction (study group) were 
selected, and studied in the non-pregnant state. Homocysteine metabolism was investigated by a standardized oral methionine 
loading test. Hyperhomocysteinemia was defined as a concentration of fasting and/or postmethionine plasma homocysteine ex­
ceeding the estimated 97.5 percentile level of the controls. In the fasting state, the vitamin status was investigated by the measure­
ment of serum and red cell folate, serum vitamin B12, and whole blood pyridoxal-5'-phosphate (PLP, an active form of vitamin 
B6). Results: Hyperhomocysteinemia was diagnosed in four controls (9%) and 26 women of the study group (31%, P < 0.05). The 
median concentrations of the vitamins studied were significantly lower in women of the study group as compared to the controls, 
except for red cell folate, where the median concentration was comparable in both groups, The median concentration of fasting 
plasma homocysteine, unlike post-methionine plasma homocysteine, was significantly higher in women who experienced placental 
abruption or infarction in their first pregnancy than in women who had the same event after one or more uncomplicated pregnan­
cies. Conclusion: Hyperhomocysteinemia is associated with placental abruption or infarction.
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1. Introduction
Homocysteine is the demethylated derivative of the 
essential amino acid methionine (Fig. 1). Homocysteine
is either transsulfurated via cystathionine into cysteine 
or it is remethylated to methionine [1]. The conversion 
of homocysteine to cystathionine is catalyzed by the 
enzyme cystathionine /3-synthase (CBS), requiring
pyridoxal-5'-phosphate (PLP), an active form of vita­
min B6, as a cofactor. In humans, at least two pathways 
exist for the remethylation of homocysteine into 
methionine [1]. One of these reactions is dependent on 
folate and vitamin B12 (Fig. 1).
* Corresponding author, Tel.: +31 80614725; Fax: +31 80541194.
Defects in either the transsulfuration or remethylation 
pathway lead to accumulation of homocysteine resulting
in hyperhomocysteinemia [1-3]. The most frequent 
cause of severe hyperhomocysteinemia is CBS deficien­
cy, an autosomal recessive inherited disorder. Premature 
arteriosclerosis and thrombosis are the most life-
threatening complications in these patients [4], 
Heterozygosity for CBS deficiency and thermolabile 
methylenetetrahydrofolate reductase (MTHFR, see Fig. 
1) cause moderately elevated levels of blood homo­
cysteine [5-8]. Mild hyperhomocysteinemia is a well- 
known risk factor for premature vascular disease
[9-11].
In a preliminary study, hyperhomocysteinemia was 
reported as a possible risk factor in women with recur-
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Fig.!. Simplified scheme of methionine-homocysteine metabolism and 
the most important enzymes and related vitamins. (1) Cystathionine 0- 
synthase; (2) 5-methyltetrahydrofolate homocysteine methyl transfer­
ase; (3) 5,10-methylenetetrahydrofolate reductase. SAM, S-adeno- 
sylmethionine; SAH, S-adenosylhomocysteine; THF, Tetrahydro- 
folate; 5-m-THF, 5-methyltetrahydrofolate; 5,10-m-THF, 5,10- 
methylenetetrahydrofolate.
rent spontaneous abortion or placental abruption [12]. 
Recently, the results of an extended study of hyper- 
homocysteinemia in women with unexplained recurrent
early pregnancy loss were presented [13]. In the present 
study, we report the results of an extended investigation 
in 84 women with placental abruption or infarction.
2. Subjects and methods
2.1. Subjects
Placental abruption and placental infarction were 
defined by clinical, laboratory and histologic standards. 
The diagnosis of placental abruption was based on 
either the combined presence of a tender, hypertonic
uterus and disseminated intravascular coagulation, 
and/or the histologic observation of a retroplacental he­
matoma with or without signs of infarction. Placental 
infarction was diagnosed if the placenta was characteriz­
ed by circumscribed areas of villous necrosis combined 
with a stillborn fetus or a severe growth-retarded child, 
i.e. having a birth weight below the 10th percentile for 
gestational age. Data on clinical and laboratory features 
were collected by interview and hospital records. 
Histologic data were drawn from various pathologists* 
reports. Eighty-four women who were referred to the 
hospital because they had a history of placental abrup­
tion or infarction fulfilled the clinical, laboratory and 
histologic standards (study group). Forty-four women 
(52%) had experienced abruption of the placenta, 
whereas the remaining 40 women (48%) had suffered
from placental infarction (as a first event). As controls,
46 women (aged 27-44 years) having at least one live- 
born child (range 1-4), and without a history of neural 
tube defect, (recurrent) spontaneous abortion, fetal
death, fetal growth retardation or placental abruption, 
were recruited by public advertisement. All participants 
{n = 130) were generally healthy and had no evidence of 
diabetes mellitus, renal or liver dysfunction. The study 
was approved by the Ethical Committee of the Univer­
sity Hospital Nijmegen St. Radboud, Nijmegen, The 
Netherlands. Before participation informed consent was 
obtained from all subjects.
2.2. Investigation procedure
Homocysteine metabolism was investigated by a stan­
dardized oral methionine loading test. After an over­
night fast, venous blood samples were collected to 
measure the concentrations of plasma homocysteine and 
blood vitamins (folate, vitamin B12, and PLP). 
Thereafter, L-methionine, 0.1 g (0.7 mmol) per kg body
weight, was administered orally in 200 ml orange juice, 
All women used a standardised methionine-restricted 
breakfast and luncheon. No drinks, except for coffee 
and tea without milk were allowed during the test proce­
dure. After 6 h, a venous blood sample was drawn to 
assay the postmethionine plasma homocysteine concen­
tration. To minimize possible hormonal influences on 
methionine-homocysteine metabolism, the loading tests
were performed about 1 week before the expected first 
day of the next menstrual period. Women were 
instructed not to become pregnant until completing the 
investigation procedure. They were not allowed to take
oral contraceptives, hormonal and/or vitamin sup­
plements, or other medication which could possibly in­
terfere with methionine-homocysteine metabolism, for 
at least 3 months prior to the oral methionine loading
test [14]. Women were tested at least 2 months after 
completing their last pregnancy (median time interval of 
the study and control group, 6 and 49 months, respec­
tively)
Hyperhomocysteinemia was defined as a fasting 
and/or postmethionine plasma homocysteine concentra­
tion exceeding the estimated 97.5 percentile level of the 
controls.
2.3. Sample preparation and analysis
Blood samples for measurements of total homo­
cysteine concentrations in plasma were drawn in
ethylenediamine tetraacetate (EDTA) vacutainer tubes 
of 4 ml and centrifuged within 30 min at 3000 X g for 
10 min. The plasma was separated and stored at -20°C 
Total homocysteine concentrations were measured by 
high-performance liquid chromatography (HPLC) tech­
nique and fluorometric detection (detection limit 0.5 
fimol/1; intra- and inter-assay coefficients of variation,
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Fig. 2. Individual concentrations of fasting plasma homocysteine in 
women of the control (n = 46) and study group (n = 84).
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Fig. 3. Individual concentrations of postmethionine plasma homocys 
teine in women of the control (n =; 46) and study group (n = 84).
both <5%) [15,16], Dry and heparinized vacutainer 
tubes of 10 ml were used for collecting venous blood 
samples to assay the concentrations of folate (serum and 
red cells), vitamin B12 (serum), and PLP (whole blood). 
Folate and vitamin B12 concentrations were measured 
simultaneously with Dualcount SPB (solid phase boil) 
Radioassay (Diagnostic Products Corporation, Los 
Angeles, CA), as described previously [17]. Determina­
tion of PLP was performed by HPLC technique [18].
2.4. Data analysis
In controls, the 2.5 and 97.5 percentile levels of plas­
ma homocysteine and blood vitamins were calculated as 
means ± 1.96 standard deviations (S.D.) after log 
transformation. In women of the study group, true 2.5
and 97.5 percentile values were established. Wilcoxon 
rank sum test was used to analyze the quantitative dif­
ferences, and uncorrected chi-square test to analyze the 
proportional differences between the two groups
studied. Spearman’s rank correlation was used to mea­
sure the associations between variables. P-values were 
two-tailed, andP < 0.05 was considered statistically sig­
nificant.
3* Results
Figs. 2, 3 depict the individual concentrations of fast­
ing and postmethionine plasma homocysteine in the
control and study group, respectively. In the control 
group, fasting plasma homocysteine concentrations 
ranged from 6 to 19 ¿tmol/1, and postmethionine plasma 
homocysteine concentrations from 20 to 55 ¿tmol/1. The
97.5 percentile levels of fasting and postmethionine plas­
ma homocysteine in controls were calculated as 15 and 
51 /rniol/1, respectively. In the study group, fasting plas­
ma homocysteine concentrations varied from 6 to 36
¿unol/1, and postmethionine plasma homocysteine con­
centrations from 16 to 97 pimol/I. Hyperhomocys- 
teinemia, i.e. fasting plasma homocysteine >15 /xmol/1 
and/or postmethionine plasma homocysteine >51 
/¿mol/1, was present in four of 46 (9%) controls and 26 
of 84 (31%) women of the study group (Table 1; uncor­
rected chi-square, 8.3; P < 0.05).
The median concentrations of plasma homocysteine 
and blood vitamins are presented in Table 2. Median 
fasting and postmethionine plasma homocysteine were 
significantly higher in the study group as compared to 
the control group. The median concentrations of the vi-
Table 1
Prevalence of hyperhomocysteinemia in women of the control and study group as related to the level of fasting and postmethionine plasma 
homocysteine
Fasting plasma 
homocysteine
Normal
High
Normal
High
Postmethionine plasma 
homocysteine
Normal
Normal
High
High
Control group
(in = 46)
42 (91%) 
3 (7%)
1 (2%) 
0 (0%)
Study group 
(n = 84)
58 (69%) 
11 (13%) 
5 (6%) 
10 (12%)
Values represent numbers (proportions).
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Table 2
Concentrations of plasma homocysteine and blood vitamins in women of the control and the study group
Control group 
(n = 46)
Study group 
(n = 84)
P-valuea
Fasting plasma homocysteine (/¿mol/1) 9 (6-19) 11 (6-36) <0.05
Postmethionine plasma homocysteine (/¿mol/I) 29 (20-55) 37 (16-97) <0.05
Serum folate (nmol/1) 14 (7-25) 12 (3-35) <0.05
Red cell folate (nmol/1) 500 (310-1000) 510 (150-1300) 0.95
Serum vitamin B12 (pmoL/1) 270 (100-580) 230 (60-620) <0.05
Whole blood PLP (nmol/1) 53 (27-160) 42 (18-85) <0.05
Values represent medians (minimum-maximum ranges). PLP, Pyridoxal-5'-phosphate. 
aWilcoxon rank sum test.
tamins studied were significantly lower in women of the 
study group as compared to the controls, except for red 
cell folate, where the median concentration was compar­
able in both groups.
In the control as well as study group, fasting and 
postmethionine plasma homocysteine were significantly 
and positively correlated (r = +0.66 and r = +*0.61, 
respectively). Table 3 lists the associations between plas­
ma homocysteine and blood vitamins in women of the 
control and study group. Fig. 4 depicts scatter diagrams 
of the concentrations of folate and vitamin B12 related
to plasma homocysteine in women of the study group.
The median concentrations of fasting and 
postmethionine plasma homocysteine were not 
significantly different between the subgroups classified 
either by the type of the first event or the number of 
events (Table 4). The median concentration of fasting 
plasma homocysteine, unlike postmethionine plasma 
homocysteine, was significantly higher in women who
experienced abruption or infarction in their first preg­
nancy than in women who had the same event after one 
or more uncomplicated pregnancies,
4. Discussion
The major finding of the present study is a high preva­
lence of hyperhomocysteinemia in women who ex­
perienced placental abruption or infarction. This result 
confirms an earlier preliminary report from our labora­
tory [12],
Placental abruption, a life-threatening event for the
mother and her child, is thought to be the result of sud­
den rupture of the spiral artery. It often develops 
simultaneously with placental infarction which also 
markedly increases the risk of fetal or neonatal death
[19], Infarction of the placenta is predominantly the 
result of spiral artery occlusion in the myometrium or 
decidua. Histologic examination of the spiral arteries in 
placental infarction usually reveals one or more signs of
vasculopathy, i.e. atherosis, narrowing, necrosis and 
thrombosis [19-23].
The hypothesis that elevated concentrations of plas­
ma homocysteine affect the placenta is supported by the
reported case of a woman with homocystinuria in whom 
four pregnancies resulted in intrauterine fetal death with 
multiple infarctions in the placenta [24]. As yet, the 
question how high levels of homocysteine may affect the 
spiral arteries is unanswered. Abnormalities of endothe­
lial cells, platelets, clotting factors, serum lipids, or dis­
orders in the complex interaction of these factors have 
been held responsible for the vascular damage and
thrombogenesis in hyperhomocysteinemia [1,9,10], In 
humans, the concentration of homocysteine in plasma is 
probably dependent on the extracellular homocysteine
Table 3
Associations between plasma homocysteine and blood vitamins in women of the control and study group
Control group (n = 46) Study group (n = 84)
Fasting plasma 
homocysteine
Postmethionine plasma 
homocysteine
Fasting plasma 
homocysteine
Postmethionine plasma 
homocysteine
Serum folate -0.43t -0.48t -0.57t -0.4lt
Red cell folate +0.07 +0.11 -0.47f -0.24f
Serum vitamin B12 +0.08 +0.07 —0.35f -0.18
Whole blood PLP +0.03 +0.04 —0.11 -0,11
Values represent Spearman’s rank correlation coefficients. PLP, Pyridoxal-5'-phosphate, 
tStatistically significant (P < 0.05).
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homocysteine in women of the study group. The dotted lines indicate the estimated 2.5 and 97.5 percentile levels of the control group.
export and on the capacity of homocysteine degradation
in mainly the liver and kidney [25]. In endothelial cells 
in vitro, a delicate equilibrium exists between homocys­
teine export and degradation. Any disequilibrium 
resulting in hyperhomocysteinemia may contribute to
the vulnerability of the endothelial cells [26]. 
Hyperhomocysteinemia may result from disorders in
the transsulfuration or remethylation of homocysteine 
[1]. Vitamin deficiencies due to malabsorption or mal­
nutrition, or enzymatic defects may interfere with both 
routes [2,3]. Hibbard (1964) has already suggested a 
higher prevalence of defective folate metabolism in 
women with placental abruption compared to controls, 
as indicated by their excessive forrnimino-glutamic acid
28
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Table 4 . .
Concentrations of fasting and postmethionine plasma homocysteine m 
women of the study group as classified by the type and pregnancy 
number of the first event, and the numbers of events
Fasting plasma
homocysteine
(¿imoVl)
Type of first event
Abruption (n = 44) 12 (7-36)
Infarction (n = 40) 11 (6-35)
P-value* 0.28
Pregnancy number (G) of first event
G a 1 {n = 46) 12 (6-36)
G > 1 (/» = 38) 10 (6-29)
P-value® 0.04
Number of events
One (/I =s 66) 11 (6-36)
Two or more («= 18) 13 (6-35)
P-valuea 0.21
Postmethionine 
plasma 
homocysteine 
(pmol/l)
38 (23-97)
36 (16-87)
0.60
39 (23-87) 
35 (16-97) 
0.13
38 (22-97) 
36 (16-78) 
0.46
Values represent medians (minimum-maximum ranges). 
aWile oxo n rank sum test.
in vascular patients with hyperhomocysteinemia 
[29-32]. It is not known whether biochemical nor­
malization of hyperhomocysteinemia by periconcep* 
tional folate administration will favour pregnancy 
outcome in women with placental abruption or infarc­
tion. A randomized controlled prevention trial should 
provide the answer to this important question.
In conclusion, hyperhomocysteinemia is associated 
with placental abruption or infarction.
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